Abstract:The World Health Organization and others warn that substandard and falsified medicines harm health and waste money, especially in low- and middle-income countries. However, no country has measured the market-wide extent of the problem, and no standardized methods exist to estimate the prevalence of either substandard or falsified medicines. This is, in part, because the task seems overwhelming; medicine markets are huge and diverse, and testing medicines is expensive. Many countries do operate some form of postmarket surveillance of medicine, but their methods and goals differ. There is currently no clear guidance on which surveillance method is most appropriate to meet specific public health goals. In this viewpoint, we aimed to discuss the utility of both case finding and risk-based sentinel surveillance for substandard and falsified medicines, linking each to specific public health goals. We posit that choosing the system most appropriate to the goal, as well as implementing it with a clear understanding of the factors driving the production and sale of substandard and falsified medicines, will allow for surveillance resources to be concentrated most efficiently. We adapted principles used for disease outbreak responses to suggest a case-finding system that uses secondary data to flag poor-quality medicines, proposing risk-based indicators that differ for substandard and falsified medicines. This system potentially offers a cost-effective way of identifying "cases" for market withdrawal, enhanced oversight, or another immediate response. We further proposed a risk-based sentinel surveillance system that concentrates resources on measuring the prevalence of substandard and falsified medicines in the risk clusters where they are most likely to be found. The sentinel surveillance system provides base data for a transparent, spreadsheet-based model for estimating the national prevalence of substandard and falsified medicines. The methods we proposed are based on ongoing work in Indonesia, a large and diverse middle-income country currently aiming to achieve universal health coverage. Both the case finding and the sentinel surveillance system are designed to be adaptable to other resource-constrained settings.

Measuring sampling plan utility in post-market surveillance of medical product supply chains

Inferring sources of substandard and falsified products in pharmaceutical supply chains

Testing at the Source: Analytics-Enabled Risk-Based Sampling of Food Supply Chains in China

Bayesian Safety Surveillance with Adaptive Bias Correction

Adaptive sampling method to monitor low‐risk pathways with limited surveillance resources

Attribute Sampling Plan for Submitted Lots Based on Prior Information and Bayesian Approach

Bayesian Approach for Design and Analysis of Medical Device Trials in the Era of Modern Clinical Studies

Information‐based group sequential design for post‐market safety monitoring of medical products using real world data

Continuous Post-Market Sequential Safety Surveillance with Minimum Events to Signal

An improved skip-lot sampling scheme with resampling mechanism using an advanced capability index

Quantitative Safety Monitoring in Clinical Trials: Application of Multiple Statistical Methodologies for Infrequent Events

Value for money of medicine sampling and quality testing: evidence from Indonesia

A variable-type skip-lot sampling plan for products with a unilateral specification limit

Bayesian accelerated acceptance sampling plans for a lognormal lifetime distribution under Type-I censoring

Robust safety monitoring and signal detection using alternatives to the standard poisson distribution

SAMPLING STRATEGIES FOR DETECTING RARE IMPURITIES: AN APPLICATION IN GENE THERAPY PRODUCTS

Applying the Bayesian Technique in Designing a Single Sampling Plan

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance

Developing a skip-lot sampling scheme by variables inspection using repetitive sampling as a reference plan

Simultaneous Confidence Intervals for Signal Detection and Ascertaining Precision of Adverse Event Rates in Clinical Trials

Designing and Selection of Mixed Relational Complete Chain Sampling Plan Using Variance Principle (RCCSP-VP)